[ALA Client News] Sonomind secures €3 million to advance its novel neuromodulation ultrasound device and opens a new therapeutic pathway in psychiatry and neurology ala.associates/funding/sono... @cnrs.fr @espciparispsl.bsky.social #neurology #funding #neuromodulation #depression

🖨️ #3DPrinting: Electronic devices that dissolve in water could make it easier to create and recycle technology prototypes – and they could even inspire more sustainable commercial devices - @jeremyhsu.bsky.social for @newscientist.com www.newscientist.com/article/2493... #sustainability

[ALA Client News] Genoskin Raises $8.7M Series A to Advance Ethical, Human Based Models That Deliver Reliable Insights for Safer, More Predictive Drug Development ala.associates/funding/geno... #drugdevelopment #immunotoxicology #funding

[ALA Client News] SOM Biotech receives positive EMA COMP opinion on European Orphan Drug Designation for SOM3355 for treatment of Huntington’s Disease 👉 ala.associates/regulatory/s... #huntingtonsdisease #neurology

Celebrating our clients' media successes🌟 Here are some of our recent highlights: 1️⃣ PLL Therapeutics in Drug Discovery World. PLL' CEO Jean-Pascal Zambaux presented the company's strategic approach for early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at Bioshares Biotech Summit

[ALA Client News] Naobios, Nuvonis and European Vaccine Initiative collaborate on manufacturing influenza challenge agent ala.associates/partnership/... #biotech #vaccines

[ALA Client News] BioWin Days 2025 : Belgian health innovators set to meet on September 23 and 24 ala.associates/events/belgi... #biotech #healthtech

[ALA Client News] Ciliatech obtains CE mark for eye implant Intercil® Uveal Spacer, novel treatment for patients with glaucoma ala.associates/regulatory/c... #Ophthalmology #Glaucoma #CEmark #ESCRS #MedTech

[ALA Client News] Meteor Biotech installs spatial biology platform, CosmoSort, at Magnify, CNSI incubator on UCLA campus ala.associates/partnership/... #SpatialCellSorting #DrugDevelopment #Oncology #Immunology #Neurology

[ALA Client News] Roca Therapeutics secures first-ever @ema.europa.eu recognition of Radiation Maculopathy as distinct indication - and Orphan Drug Designation ala.associates/regulatory/r... #Oncology #ClinicalTrials #Opthalmology #Radiotherapy

Researchers have developed antibiotics that can potentially kill drug-resistant gonorrhoea and MRSA with the help of artificial intelligence - @the-independent.com www.independent.co.uk/news/science... #antibiotics #antimicrobialresistance #AI

Scientists say this could be the start of a "new generation" of tech, capable of hacking the gut microbiome www.sciencefocus.com/news/gut-mic... #microbiome #guthealth #healthtech

Scientists have found the first robust evidence that genes affect chances of #ME/CFS, a mysterious and debilitating illness that has been neglected and dismissed for decades by many in the medical community - @iansample.bsky.social for @theguardian.com www.theguardian.com/society/2025...

[ALA Client News] PLL Therapeutics presents strategic approach for early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at Bioshares Biotech Summit 🧬 ala.associates/events/pll-t... #ALS #diagnostics #neurodegenerative

🦠 A UK government-funded study shows that without concerted action, increased rates of antimicrobial resistance (AMR) could lead to global annual GDP losses of $1.7tn over the next quarter of a century - @theguardian.com www.theguardian.com/society/2025... #AntimicrobialResistance #Antibiotics

💻 AI companies have now mostly abandoned the once-standard practice of including medical disclaimers and warnings in response to health questions, new research has found - @jamesmodonnell.bsky.social for @technologyreview.com www.technologyreview.com/2025/07/21/1... #AI #Healthcare

[ALA Client News] Corteria Pharmaceuticals initiates Phase 2 trial in heart failure and Phase 1 trial in obesity with its first-in-class CRF2 agonists Learn more here 👇 ala.associates/clinical/cor... #biotech #obesity #cardiovascular

Researchers have found the first new type of magnet in nearly a century. Now, these strange "altermagnets" could help us build an entirely new type of computer - @jacklinkwan.bsky.social for @newscientist.com www.newscientist.com/article/2487... #magnets #computing

AI-trained robot carries out procedures on dead pig organs to remove gall bladders without any human help - @robert-booth.bsky.social for @theguardian.com www.theguardian.com/science/2025... #AI #Surgery #Robotics

[ALA Client News] VIVES Partners joins Nuclidium AG’s €84M Series B financing Learn more about VIVES’ newest investment 👇 ala.associates/funding/vive... #VC #Radiopharmaceuticals #Oncology #Biotech

Celebrating our clients' media successes🌟 1️⃣ Accure Therapeutics in the New Barcelona Post. The company secured funding from The Michael J Fox Foundation to advance development of drug candidate For #Parkinsons 🧠 www.thenewbarcelonapost.com/accure-therapeutics-recibe-15-millones-farmaco-parkinsons

[ALA Client News] Ciloa secures €6.5M government funding from #France2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of obesity and type 2 diabetes ala.associates/funding/cilo... #Diabetes #Obesity #MetabolicDiseases @bpifrance-officiel.bsky.social

[ALA Client News] Ciloa secures €6.5 million government funding from France 2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of #obesity and type 2 #diabetes Learn more👇 ala.associates/funding/cilo... #France2030 @bpifrance-officiel.bsky.social

[ALA Client News] @carthera.bsky.social receives EMA expert panel endorsement for Orphan Medical Device status of SonoCloud system for glioblastoma 👉 ala.associates/regulatory/c... #Glioblastoma #Oncology #MedTech #NeuroOncology

[ALA Client News] Novadip and Cliniques universitaires Saint-Luc report positive results for compassionate use of NVD003 on four pediatric patients 👉 ala.associates/clinical/nov... NVD003 is a bone grafting material developed to surgically treat patients with CPT, a rare #pediatric disease

[ALA Client News] Endo Tools Therapeutics and Fujifilm Middle East FZE partner to extend access to innovative treatments for #obesity 👉 ala.associates/partnership/... Partnership enables distribution of endomina product range across 18 countries in Middle East and Africa #endoscopy #medicaldevice

[ALA Client News] VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by DanoNE 👉 ala.associates/corporate/vi... Deal marks significant achievement for early-stage fund VIVES Partners in successfully transforming research into strategic market value #guthealth

[ALA Client News] Oxeltis and academic partners receive grant funding worth nearly €800,000 to develop antiviral for Bunyaviricetes 👉 ala.associates/funding/oxel... @agencerecherche.bsky.social

[ALA Client News] PLL Therapeutics welcomes Dr. Philippe Corcia, leading genetics and rare disease specialist, to scientific board 👉 ala.associates/appointment/... Appointment follows recent launch of multi-stage, phase I/II trial of drug candidate PLL001 #ALS

[ALA Client News] Novadip receives RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia 👉 ala.associates/regulatory/n... #biotech @fda.gov

[ALA Client News] Meteor Biotech selected to deliver keynote talk at Hong Kong International Oncology Forum 2025 (HKIOF) 👉 ala.associates/events/meteo... #Keynote #HKIOF #SpatialCellSorting #Oncology

[ALA Client News] Oxeltis and Molecular Forecaster forge strategic collaboration to enhance client's drug design and synthesis 👉 ala.associates/partnership/...

[ALA Client News] Meteor Biotech opens US office on UCLA campus to support biomedical research partners in North America 👉 ala.associates/corporate/me... #USOffice #SpatialCellSorting #DrugDevelopment

[ALA Client News] Enalees launches Rhéa, new range of rapid molecular tests intended for ruminants 👉 https://bit.ly/3FMMUnL ##veterinarians

🌟 June is Brain and Alzheimer's Awareness Month! 🌟 Did you know that over 50 million people worldwide are living with Alzheimer's and other dementias? By increasing awareness, we can help reduce stigma and promote early detection and intervention @alzassociation.bsky.social #EndALZ #Alzheimers

[ALA Client News] Scintil Photonics welcomes Jim Theodoras as vice-president of product development 👉 ala.associates/appointment/... #siliconphotonics #datacenters #AI #opticalcommunications

🌟 Celebrating clients’ coverage and success - Quidditas Therapeutics in @lechobe.bsky.social www.lecho.be/entreprises/... - Massalia Therapeutics in European Biotechnology News european-biotechnology.com/latest-news/... - Sonomind SAS in BioWorld www.bioworld.com/articles/719...

🌟 Celebrating clients’ coverage and success We are happy to share some of the articles we obtained for our clients this month 👇 - BHealthCare in @lesechosfr.bsky.social www.lesechos.fr/pme-regions/... - Clean Biologics in Discover Pharma discover-pharma.com/new-ceo-to-s...

[ALA Client News] Massalia Therapeutics launches to advance novel therapies for patients with complex conditions intersecting oncology and fibrosis 👉 ala.associates/corporate/ma... #Biotech #Launch #Oncology #Fibrosis

[ALA Client in the News] Sonomind à l’honneur sur @bfmtv.com La neuromodulation par ultrasons a permis une réduction de + de 60 % de la sévérité de la dépression au 5ème jour du protocole (étude publiée dans Brain Stimulation) A revoir ici 👇 www.bfmtv.com/sante/sante-... #medtech #depression

[ALA Client News] BHealthCare signs agreements with three European medical labs for 30+ pre-orders of its autonomous blood drawing device 👉 ala.associates/partnership/... #Medtech #Robotics #Blood #Collecting #Robot

[ALA Client News] Quidditas raises €2.62M to accelerate development of pioneering genome editing technology 👉 ala.associates/funding/quid... #GenomeEditing #Funding #Biotech

[ALA Client News] Clean Biologics appoints Laurent Claisse as CEO to accelerate US and global market expansion 👉 ala.associates/appointment/... #Appointment #Biopharma #CRO

[ALA Client News] Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb 👉 ala.associates/clinical/novadip-releases-five-year-follow-up-results-fornvd003-regenerative-treatment-for-severe-bonenon-union-of-lower-limb/

[ALA Client News] Landmark BioVentures and G.CLIPS Biotech forge strategic alliance to address critical gaps in drug target engagement ala.associates/partnership/... #Biotech #Pharma #DrugDiscovery

[ALA Client News] #AACR2025: Meteor Biotech showcases CosmoSort, new class of spatial cell sorter enabling deeper translational cancer research ala.associates/product-laun... @theaacr.bsky.social #Biotech #AI #Oncology #DrugDiscovery

[ALA Client News] @carthera.bsky.social reaches recruitment milestone in SONOBIRD pivotal trial for recurrent glioblastoma 100 participants enrolled across Europe and US in largest trial ever performed on patients using ultrasound-based blood-brain barrier opening ala.associates/clinical/car...

[ALA Client News] Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogeneic product, in spine fusion 👉 ala.associates/clinical/nov... #biotech #RegenerativeMedicine #orthopedics

💥 [ALA Client News] PLL Therapeutics enrolls first patient in Phase I/II trial of drug candidate PLL001 for Amyotrophic Lateral Sclerosis (ALS) 👉 ala.associates/clinical/pll... #biotech #clinicaltrials #ALS #diagnostics

💥[ALA Client News] Medicud secures over EUR 1.3 million in oversubscribed seed funding round to initiate pivotal trial of innovative wound healing device 👉 ala.associates/funding/medi... #medtech #funding #VC